Literature DB >> 11018693

Use of tumor markers for differential diagnosis of mesothelioma and secondary pleural malignancies.

C Fuhrman1, J C Duche, C Chouaid, I Abd Alsamad, K Atassi, I Monnet, J P Tillement, B Housset.   

Abstract

STUDY
OBJECTIVE: The aim of the study was to assess diagnosis value of tumor markers for differential diagnosis between mesothelioma and other pleural tumors. DESIGN AND METHODS: Prospective study of 85 patients attending our hospital with malignant pleural effusion. The diagnostic approach involved routine pleurocentesis followed by pleural needle. When precise diagnosis was not achieved, thoracoscopy with pleural biopsies was performed. Carcinoembryonic antigen (CEA), hyaluronic acid, tissue polypeptide antigen and cyfra 21 to 1 were measured in serum and pleural fluid.
RESULTS: By using receiver operating characteristics curves and area under curves, the best diagnostic characteristics were obtained with pleural and serum CEA concentrations. The area under the curve was larger for pleural ACE than for serum ACE. The sensitivity and specificity of a pleural CEA level exceeding 3 ng/mL for ruling out the diagnosis of mesothelioma were 100% and 77%, respectively.
CONCLUSION: A CEA level above 3 ng/mL in pleural fluid eliminated the diagnosis of mesothelioma, whereas the other markers were not sufficiently discriminant. However, despite a negative predictive value of 100% at a cutoff of 3 ng/mL, CEA assay in pleural fluid only avoids a small number of diagnostic thoracoscopies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11018693     DOI: 10.1016/s0009-9120(00)00157-0

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  7 in total

1.  Clinical role of pleural effusion MMP-3 levels in malignant pleural mesothelioma.

Authors:  Aki Murakami; Chiharu Tabata; Rie Tabata; Hisaya Okuwa; Takashi Nakano
Journal:  Oncol Lett       Date:  2011-12-23       Impact factor: 2.967

2.  Cytological diagnosis of malignant mesothelioma--improvement by additional analysis of hyaluronic acid in pleural effusions.

Authors:  L Welker; M Müller; O Holz; E Vollmer; H Magnussen; R A Jörres
Journal:  Virchows Arch       Date:  2007-02-15       Impact factor: 4.064

3.  Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma.

Authors:  Jenette Creaney; Deborah Yeoman; Leanne K Naumoff; Michelle Hof; Amanda Segal; Arthur William Musk; Nicholas De Klerk; Nora Horick; Steven J Skates; Bruce W S Robinson
Journal:  Thorax       Date:  2007-03-13       Impact factor: 9.139

4.  Diagnostic value of mesothelin in pleural fluids: comparison with CYFRA 21-1 and CEA.

Authors:  Rosa Filiberti; Stefano Parodi; Roberta Libener; Giovanni Paolo Ivaldi; Pier Aldo Canessa; Donatella Ugolini; Barbara Bobbio; Paola Marroni
Journal:  Med Oncol       Date:  2013-03-27       Impact factor: 3.064

5.  Assessment of Confounding Factors Affecting the Tumor Markers SMRP, CA125, and CYFRA21-1 in Serum.

Authors:  Daniel Gilbert Weber; Georg Johnen; Dirk Taeger; Anne Weber; Isabelle Mercedes Gross; Beate Pesch; Thomas Kraus; Thomas Brüning; Monika Gube
Journal:  Biomark Insights       Date:  2010-01-28

Review 6.  Biomarkers for malignant pleural mesothelioma: current status.

Authors:  Laurent Greillier; Paul Baas; John J Welch; Baktiar Hasan; Alexandre Passioukov
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

7.  Pleural fluid analysis: standstill or a work in progress?

Authors:  T Hassan; M Al-Alawi; S H Chotirmall; N G McElvaney
Journal:  Pulm Med       Date:  2012-02-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.